Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Bellicum Pharmaceuticals (BLCM) announced it has regained compliance with Nasdaq's Listing Rule 5550(b)(1) after confirming stockholders' equity of at least $2.5 million.

Rhea-AI Summary

Bellicum Pharmaceuticals (BLCM) announced it has regained compliance with Nasdaq's Listing Rule 5550(b)(1) after confirming stockholders' equity of at least $2.5 million. This follows a successful private placement of equity securities that raised approximately $35 million before expenses. The company is now in compliance with the continued listing requirements of The Nasdaq Capital Market, enabling its common stock to remain listed.

Positive

• Regained compliance with Nasdaq Listing Rule 5550(b)(1) due to sufficient stockholders' equity.
• Successfully completed a private placement of $35 million, enhancing financial stability.

Negative

• None.

Argus Session date unavailable

-1.83% session move Open Argus

Details

News Market Reaction – BLCM

The recorded move for BLCM in the trading session of this news was -1.83%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the company’s recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Bellicum Pharmaceuticals raise in its recent private placement?

Bellicum Pharmaceuticals raised approximately $35 million in its recent private placement of equity securities.

What compliance issue did Bellicum Pharmaceuticals resolve with Nasdaq?

Bellicum Pharmaceuticals resolved a compliance issue regarding Nasdaq's Listing Rule 5550(b)(1) by proving it has stockholders' equity of at least $2.5 million.

What is the significance of Nasdaq Listing Rule 5550(b)(1) for Bellicum Pharmaceuticals?

The Nasdaq Listing Rule 5550(b)(1) requires companies to maintain a minimum stockholders' equity of $2.5 million to remain listed on the Nasdaq Capital Market.